Status:
UNKNOWN
An AI Model Based on Smartphone-derived Multimodality Images to Evaluate Portal Hypertension in Patients With Cirrhosis (CHESS2203)
Lead Sponsor:
Hepatopancreatobiliary Surgery Institute of Gansu Province
Collaborating Sponsors:
The Third People's Hospital of Taiyuan
QuFu People's Hospital
Conditions:
Portal Hypertension
Eligibility:
All Genders
18-75 years
Brief Summary
Portal hypertension contributed to the main complications of liver cirrhosis. Currently, hepatic venous pressure gradient (HVPG) was the reference standard for evaluating portal pressure in patients w...
Detailed Description
Portal hypertension contributed to the main complications of liver cirrhosis. Currently, hepatic venous pressure gradient (HVPG) was the reference standard for evaluating portal pressure in patients w...
Eligibility Criteria
Inclusion
- age above or equal to 18-year-old;
- fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations;
- with HVPG examination in the past 6 months;
- applied a patented technology based on mobile phone for collecting and analyzing tongue-eye-palm images
- signed informed consent.
Exclusion
- contradictions for HVPG examination;
- accepted primary prevention (non-selective beta blockers or endoscopic variceal ligation);
- accepted transjugular intrahepatic portosystemic shunt;
- diagnosed as hepatocellular carcinoma.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2023
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05402410
Start Date
May 1 2022
End Date
April 30 2023
Last Update
June 2 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHESS
Beijing, Beijing Municipality, China, 1000000
2
Institute for TCM-X, MOE Key Laboratory of Bioinformatics/Bioinformatics Division, BNRIST, Department of Automation, Tsinghua University
Beijing, Beijing Municipality, China, 100000